Clinical Trial Detail

NCT ID NCT01779050
Title Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Trastuzumab

Docetaxel

Cyclophosphamide + Epirubicin

Paclitaxel

Cyclophosphamide + Epirubicin + Fluorouracil

Carboplatin + Docetaxel

Cyclophosphamide + Docetaxel

Age Groups: adult

Additional content available in CKB BOOST